Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.

It was called ‘complement’ because it aided the antibacterial activity of antibodies. However, it is now known that the complement system can be activated early in an infection without the presence of ...

The complement system is an important part of the humoral immune defence in mammals that is formed by about 35 soluble and cell-surface proteins. Together these proteins enable the host to recognize ...